MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 596959 | Name: Fortimicin C

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Fortimicin C is a bioactive chemical.

Chemical Structure

Fortimicin C
Fortimicin C
CAS#62874-51-5

Theoretical Analysis

MedKoo Cat#: 596959

Name: Fortimicin C

CAS#: 62874-51-5

Chemical Formula: C18H36N6O7

Exact Mass: 448.2645

Molecular Weight: 448.52

Elemental Analysis: C, 48.20; H, 8.09; N, 18.74; O, 24.97

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Fortimicin C;
IUPAC/Chemical Name
N-((1S,2R,3R,4S,5S,6R)-4-amino-3-(((2R,3R,6S)-3-amino-6-((S)-1-aminoethyl)tetrahydro-2H-pyran-2-yl)oxy)-2,5-dihydroxy-6-methoxycyclohexyl)-N-methyl-2-ureidoacetamide
InChi Key
VKGIGFQBOYWLHV-APGVDKLISA-N
InChi Code
InChI=1S/C18H36N6O7/c1-7(19)9-5-4-8(20)17(30-9)31-15-11(21)13(26)16(29-3)12(14(15)27)24(2)10(25)6-23-18(22)28/h7-9,11-17,26-27H,4-6,19-21H2,1-3H3,(H3,22,23,28)/t7-,8+,9-,11-,12-,13-,14+,15+,16+,17+/m0/s1
SMILES Code
C[C@H](N)[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)[C@H](O)[C@H](OC)[C@@H](N(C(CNC(N)=O)=O)C)[C@H]2O)O1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 448.52 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Huong NL, Hoang NH, Hong SY, Sohng JK, Yoon YJ, Park JW. Characterization of fortimicin aminoglycoside profiles produced from Micromonospora olivasterospora DSM 43868 by high-performance liquid chromatography-electrospray ionization-ion trap-mass spectrometry. Anal Bioanal Chem. 2016 Feb;408(6):1667-78. doi: 10.1007/s00216-015-9281-2. Epub 2016 Jan 11. PubMed PMID: 26753981. 2: Galimand M, Courvalin P, Lambert T. RmtF, a new member of the aminoglycoside resistance 16S rRNA N7 G1405 methyltransferase family. Antimicrob Agents Chemother. 2012 Jul;56(7):3960-2. doi: 10.1128/AAC.00660-12. Epub 2012 Apr 30. PubMed PMID: 22547620; PubMed Central PMCID: PMC3393463. 3: Hasegawa M. A novel, highly efficient gene-cloning system in Micromonospora applied to the genetic analysis of fortimicin biosynthesis. Gene. 1992 Jun 15;115(1-2):85-91. PubMed PMID: 1612453. 4: Dairi T, Hasegawa M. Common biosynthetic feature of fortimicin-group antibiotics. J Antibiot (Tokyo). 1989 Jun;42(6):934-43. PubMed PMID: 2737953. 5: Hotta K, Morioka M, Okami Y. Biosynthetic similarity between Streptomyces tenjimariensis and Micromonospora olivasterospora which produce fortimicin-group antibiotics. J Antibiot (Tokyo). 1989 May;42(5):745-51. PubMed PMID: 2722689. 6: Stefani S, Debbia EA, Schito GC, Russo G. Microbiological characterization of dactimicin: antibacterial activity towards gram-positive and gram-negative bacteria. Drugs Exp Clin Res. 1989;15(3):119-23. PubMed PMID: 2752910. 7: Price KE. The potential for discovery and development of improved aminoglycosides. Am J Med. 1986 Jun 30;80(6B):182-9. Review. PubMed PMID: 3089002. 8: Moreau N, Jaxel C, Le Goffic F. Comparison of fortimicins with other aminoglycosides and effects on bacterial ribosome and protein synthesis. Antimicrob Agents Chemother. 1984 Dec;26(6):857-62. PubMed PMID: 6395800; PubMed Central PMCID: PMC180039. 9: Tadanier J, Hallas R. 3-O-demethyl-2,3-di-epi-fortimicins and 3-O-demethyl-3-epi-fortimicins. J Antibiot (Tokyo). 1983 Mar;36(3):256-66. PubMed PMID: 6833145. 10: Hirayama N, Shirahata K, Ohashi Y, Sasada Y. Conformations of fortimicins and three-dimensional structure-activity relationship in the aminoglycoside antibiotics. Mol Pharmacol. 1983 Jan;23(1):127-32. PubMed PMID: 6865896. 11: Komoda F, Ihara Y, Yokoyama S, Goto T. [Tissue distribution of fortimicin used in the field of obstetrics]. Jpn J Antibiot. 1982 Jun;35(6):1399-401. Japanese. PubMed PMID: 7131766. 12: Matsuya N, Murata M, Takaku I. [Studies on fortimicin in the field of ophthalmology]. Jpn J Antibiot. 1982 Jun;35(6):1395-8. Japanese. PubMed PMID: 7131765. 13: Kawamura S. [Clinical studies on fortimicin in otorhinolaryngological infections]. Jpn J Antibiot. 1982 Jun;35(6):1391-4. Japanese. PubMed PMID: 7131764. 14: Hosoma S, Seiko R, Ito T. [Clinical studies of fortimicin in surgical infections]. Jpn J Antibiot. 1982 Jun;35(6):1387-90. Japanese. PubMed PMID: 7131763. 15: Taguchi T, Fujita M, Tomita K, Matsunaga S, Kawahara T, Takatsuka Y, Ashimura M, Ito A, Okumura T, Kimura M. [Clinical studies of fortimicin in the field of surgery]. Jpn J Antibiot. 1982 Jun;35(6):1379-86. Japanese. PubMed PMID: 7131762. 16: Suwaki M, Ikeda M, Kashiwa N, Nohara N, Nakakita T, Yamada M. [Experimental and clinical studies of fortimicin in the field of dermatology]. Jpn J Antibiot. 1982 Jun;35(6):1374-8. Japanese. PubMed PMID: 7131761. 17: [Fortimicin preparation]. Jpn J Antibiot. 1982 Jun;35(6):1402-4. Review. Japanese. PubMed PMID: 6752463. 18: Martin JR, Johnson P, Tadanier J, Cirovic M, Stanaszek RS. Diastereomeric fortimicin 1,2-epoxides. The preparation of the 1-deamino-2-deoxyfortimicins A and B and the 1,2-di-epi-fortimicins A and B. J Antibiot (Tokyo). 1982 Jan;35(1):46-57. PubMed PMID: 7068515. 19: Okumura S, Deguchi T, Marumo H. Biosynthetic incorporation of methyl groups into fortimicins. J Antibiot (Tokyo). 1981 Oct;34(10):1360-2. PubMed PMID: 7309629. 20: Kurath P, Tadanier J, Johnson P, Grampovnik D, Egan RS, Stanaszek RS, Cirovic M, Washburn WH, Leonard JE. Substances derived from 4-de-N-methylfortimicin B. J Antibiot (Tokyo). 1981 Jun;34(6):691-700. PubMed PMID: 7275853.